FK228 (romidepsin)

DRUG2 trials

Sponsors

Celgene

Conditions

Carcinoma, Renal CellNeoplasm MetastasisProstatic Neoplasms

Phase 2

Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228

CompletedNCT00106301

CelgeneCarcinoma, Renal Cell, Prostatic Neoplasms

Start: 2004-04-01End: 2006-09-01Updated: 2019-11-18

A Research Study for Patients With Metastatic Renal Cell Carcinoma

CompletedNCT00106613

CelgeneCarcinoma, Renal Cell, Neoplasm Metastasis

Start: 2003-05-01End: 2004-08-01Updated: 2019-10-18